Ipsen - Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The company also published a corrective declaration regarding voting rights and share capital figures as of June 30, 2026.